FeesSafety
Pluang+

Teads launches next-gen Ad Manager with AI and cross-screen ad tools for unified campaign measurement.

Market News
29 Oct 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Teads launches next-gen Ad Manager with AI and cross-screen ad tools for unified campaign measurement.

Teads has introduced the latest version of its Ad Manager platform, designed to unify advertising across connected TV (CTV) and digital channels. The platform integrates AI-powered workflows, full-funnel measurement, and open integrations with major AI systems to help advertisers connect campaigns, measure impact, and optimize performance efficiently. This update addresses the challenge of fragmented media planning by enabling seamless cross-screen strategies and real-time campaign management. The new features are available now for enterprise clients, with broader access planned by the end of 2026.

Teads' new Ad Manager platform update is the subject, providing context for readers interested in technology stocks. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced stocks, 23 rose and 125 fell. ServiceNow Inc (NOW) traded at USD 120.15 with a 1-day change of -19.97%, while Marvell Technology Inc (MRVL) was priced at USD 222.51, down 11.58%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App